Cytogenetic analysis in 941 consecutive patients with haematologic disorders

Area of Science:

• Hematology
• Cytogenetics
• Oncology

Background:

• Cytogenetic analysis is crucial for diagnosing and classifying hematologic malignancies.
• Previous studies established baseline frequencies of chromosomal abnormalities in various blood disorders.
• Evaluating long-term trends in cytogenetic analysis success and findings is essential for clinical practice.

Purpose of the Study:

• To reevaluate clinical and cytogenetic findings in patients with suspected hematologic malignancies over a 12-year period.
• To assess the diagnostic sensitivity and specificity of cytogenetic analysis in differentiating malignant from benign hematologic conditions.
• To compare cytogenetic analysis outcomes between different time periods and sample types.

Main Methods:

• Retrospective analysis of 1652 cytogenetic analyses from 941 patients with suspected hematologic conditions (1973-1984).
• Inclusion of patients with acute nonlymphocytic leukemia (ANLL), chronic myeloid leukemia (CML), myelodysplasia (MDS), myeloproliferative disorders (MPD), acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma (NHL), lymphoproliferative disorders (LPD), and benign disorders.
• Comparison of results from 1973-1980 versus 1981-1984, including bone marrow and peripheral blood samples.

Main Results:

• Cytogenetic abnormalities were detected in 50% of malignant hematologic disorders (sensitivity 0.50) and only 1 benign case (specificity 0.99).
• Success rates ranged from 73-74.4% for ALL, MPD, and NHL+LPD, and 87-94% for ANLL, MDS, CML, and benign disorders.
• Age-related differences in cytogenetic patterns were observed in MDS and ANLL. Bone marrow analysis failure rates decreased over time, but overall detection rates remained stable. Peripheral blood analysis showed high failure rates.

Conclusions:

• Cytogenetic analysis is highly specific for malignant hematologic disorders but has moderate sensitivity.
• Bone marrow analysis remains the preferred sample type, offering higher success and detection rates than peripheral blood.
• Long-term data show stable diagnostic yields despite improvements in bone marrow analysis techniques.